Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Nepalese women wearing a mask

The RECOVERY trial was launched rapidly in the UK in March 2020 to investigate if any existing treatments were effective against COVID-19. It is open to all patients admitted to NHS hospitals with COVID-19. The trial has already delivered results that have changed clinical care, including the findings that the inexpensive steroid, dexamethasone, and the anti-inflammatory treatment, tocilizumab, significantly reduce the risk of death when given to hospitalised patients with severe COVID-19.

Peter Horby, Professor of Emerging Infectious Diseases and Global Health and Joint Chief Investigator for the trial, says, ‘The RECOVERY trial has been an enormous success, enrolling over 37,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies.’

‘It is particularly important to find readily available and affordable treatments for COVID-19 that can be used worldwide. RECOVERY International will help us to identify effective treatments that can be used in less well-resourced settings’ he added.

The expansion of RECOVERY internationally has been made possible thanks to the longstanding work of the Oxford University Clinical Research Unit (OUCRU), which has campuses in Kathmandu in Nepal (OUCRU Nepal) and Jakarta in Indonesia (Eijkman-Oxford Clinical Research Unit, EOCRU). In Indonesia and Nepal, the trial will initially focus on the treatments aspirin and colchicine, since these are readily available and affordable but, like RECOVERY in the UK, the trial is adaptive and new drugs will be added over time.

The full story is available on the University of Oxford website

Similar stories

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.

RECOVERY Trial launches in South Africa

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.

RECOVERY Trial wins ‘Oscar of Higher Education’ for STEM Research Project of the year

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category.

Antibiotic accountability: how countries and companies perform

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.

New! A learning framework about antimicrobial resistance for children and young people

A downloadable resource for educators, health & research professionals to help develop young peoples’ understanding of AMR and positive actions they can take to mitigate it.